ABSTRACT: We recently produced a species-specific monoclonal antibody (MAb-001) against a surface antigen of Cryptobia salmositica Katz 1951 When a single dose (4 % body of weight in ml) of MAb-001 was injected into fish infected with C. salmositica, subsequent parasitaemias were significantly (p < 0.05) reduced at 48 h after treatment. Parasitaemias were still significantly lower than in control fish (injected with cold-blooded vertebrate Ringer's solution, CBVR) 1 wk after injection of MAb-001. There was no significant difference in parasitaemias between injection of a single dose or a double dose of MAb-001. Injection of MAb-001 into fish before infection and at 1 wk after infection did not prevent infection. Parasitaemias in fish which received MAh on Days 0, 1, 2, 3, 4 , 5, 6 (daily injected flsh) were sign~flcantly h~gher than in fish which received CBVR. The production of complement-fixing antibody against C salmositica in MAb daily injected fish was significantly lower than in those injected with CBVR. Antibodies against MAb-001 were detected in fish injected daily with MAb-001 These results suggest that a single dose of MAb-001 is therapeutic and perhaps can be used to prevent mortality of infected fish. Injection of MAb-001 every day in the first week after infection induced significant antigenic competition between parasites and MAb-001 Consequently, these fish produced less complement-fixing antibody against C. salmositica and this resulted in higher parasitaemias than in CBVR-injected fish.
INTRODUCTION
Cryptobia salmositica Katz 1951 is a pathogenic haemoflagellate in salmonids on the west coast of North America and natural infections have been reported in all species of Pacific salmon (Woo 1987 (Woo , 1994 . Rainbow trout Oncorhynchus mykiss are susceptible to infection and develop clinical disease with exophthalmia, abdominal distension with ascites, splenomegaly, anemia and anorexia (Woo 1979 , Thomas & Woo 1992 ). Considerable efforts have been directed to understand the protective mechanism in fish against this parasite. In vitro and in vivo cell mediated immune responses (TDTFI reaction, phagocytosis, MMI) have 'Addressee for correspondence. E-mail: pwoo@uoguelph.ca been demonstrated in experimentally infected rainbow trout (Thomas &Woo 1990 , Li &Woo 1995 , Feng & Woo 1996 . Both agglutinating and complement-fixing antibodies were detected in infected and vaccinated rainbow trout (Jones & Woo 1987 , Woo & Li 1990 , SitjaBobadilla & Woo 1994 , Li & Woo 1995 , Feng & Woo 1996 , and an in vitro assay has been used to evaluate the importance of antibodies in protective immunity against C. salmositica. Passive transfer of antibodies against C. salmositica from immune fish to nonimmune fish showed partial protection (Jones & Woo 1987) . In a recent study, we (Feng & Woo 1996) produced a species-specific monoclonal antibody against a surface antigen on C, salmositica. This antibody is cytotoxic to C. salmositica under in vitro conditions.
Monoclonal antibodies with in vitro cytotoxity have been produced against mammalian protozoans, i.e.
Plasmodium knotvlesi, P. falciparum, P. chabaudi, Trypanosoma brucei rhodesiense, T, cruzi, Giardia lamblia, and G. muris (see Epstein et al. 1981 , Boyle et al. 1982 , Saul et al. 1984 , Pinder et al. 1987 , Araguth et al. 1988 , Bustcher et al. 1988 , Campbell & Faubert 1994 , and against a fish parasite, Ichthyophthirius multifiliis (see Lin et al. 1994) . However, only a few of them are known to be protective in the host. Monoclonal antibodies against the rodent malaria parasites P. chabaudi and P. yoelii delayed and decreased parasitaemias when they were injected into infected animals (Freeman et al. 1980 , Boyle et al. 1982 . A strain-specific MAb against G. lamblia is cytotoxic under in vitro conditions and MAbs against G. muris are therapeutic (Nash & Aggarwal 1986 , Butscher & Faubert 1988 . Monoclonal antibody against I. multifiliis protected fish from infection when it was injected intraperitoneally into channel catfish (Lin et al. 1994) .
The aims of the present study were to examine the therapeutic and prophylactic effects of MAb-001 on acute Cryptobia salmositica infection in rainbow trout.
MATERIAL AND METHODS
Source and maintenance of fish. A total of 160 disease-free juvenile rainbow trout Oncoryhnchus mykiss purchased from a local hatchery (Wildcat Trout Farm, Thamesford, Ontario, Canada) were used in the study. The fish (weight approximately 10 to 15 g and 10 to 15 cm in length) were maintained in plastic circular tanks (128 1) with constant aeration and flowing well water. The water temperature varied between 6.5 and 13°C during the year. Fish were held under a 12 h light:l2 h dark photoperiod, and were fed daily to satiety with commercial trout diet (Martin's Feed Mills, Elmira, Ontario).
Branding and bleeding. Fish were anaesthetized in a 200 ppm solution of tricaine methanesulfonate (MS222) (Finquel Brand, Argent Chemical Laboratories, Redmond, WA 98052, USA) before branding or bleeding. The caudal and anal fins of some fish were branded using a 15 A wood-burning iron according to the method of McNical & Noakes (1979) to provide individual identification.
A disposable sterile needle (G) and a 1 rnl disposable plastic syringe were used to withdraw blood from the caudal vein into heparinized saline (0.1 g heparin added to 10 m1 cold-blooded vertebrate Ringer's saline (CBVR) (Woo 1979) . Blood samples were kept on ice until they were processed. Determination of parasitaernia. The parasitemia was determined using a haemocytometer (Archer 1965) . Briefly, blood from a fish infected with parasites was diluted (from 1:10 to 1:200) with ice-cold Ringer's saline in a white or a red blood cell dilution pipette (Fisher USA). The pipette was shaken for 30 s on a Yankee pipette shaker. The suspension was dispensed into a haemocytometer and the number of parasites counted under a compound microscope at 160x magnification.
The haematocrit centrifuge technique (Woo & Wehnert 1983) was used when there was less than one Cryptobia salmositica per microscope field (Ocular X 10 and Objective X 16). A volume of 0.05 m1 fish blood was drawn into a heparinized microhaemotocrit capillary tube. The tube was sealed on one end with Critoseal and centrifuged in an ice-cold IEC MB centrifuge at 13 000 X g for 4 min. The tube was placed on a glass slide with a small drop of immersion oil at the junction of packed white cells and plasma. Parasites at the buffy layer were detected under a compound microscope at lOOx magnifications.
Determination of complement-fixing antibodies using in vitro lysis test (Li & Woo 1995 (Woo & Li 1990) were washed 3 times with ice-cold Ringer's saline. The parasites were resuspended and counted using a haemocytometer. The suspension was diluted with ice-cold Ringer's sallne until 1 m1 contained approximately 4.0 X 103 parasites (approximately 100 parasites per 25 p1). A volume of 25 p1 freshly collected plasma from naive adult rainbow trout (as a source of complement) and 25 p1 of parasites suspension were added into each well containing the diluted antiserum. The plate was examined under an inverted microscope at 1.0 X 102 magnifications for living parasites 3 h after incubation at 10°C. The titre of complement-fixing antibodies was the maximum antiserum dilution in which all parasites were lysed. Production and isotyping of monoclonal antibody. Hybridomas were generated (Feng & Woo 1996) by immunizing BALB/c mice (Charles River Canada Inc., St. Constant, Quebec) intraperitoneally with 1 X 107 washed live Cryptobia salmositica from cultures. The technique for producing hybridomas was as described by Oi & Herzenberg (1980) with some modifications (Lam et al. 1987) . Briefly, mouse spleen cells (5 wk after immunization) were fused with NS-1 myeloma cells in a 10:l ratio using PEG fusogen [40% polyethylene glycol (PEG; Sigma), 4 % dimethyl sulfoxide (DMSO; Sigma) in Dulbecco's Modified Eagle Medium (D-MEM; Gibco]. The hybrldomas were selected with HAT-medium and incubated at 37OC in a 5 % CO2 incubator, screened for production of antibodies against C . salmositica using ELISA (Feng & Woo 1996) and positive hybridomas were then cloned by the limited dilution method (Lam et al. 1987) or using the 'single cell pick' method of Harlow & Lane (1988) . One positive hybridoma was selected; the monoclonal antibody it produced was designated MAb-001.
MAb-001 was isotyped using a ELISA-based Mouse Typer Isotyping Kit (Bio-Rad). Large volunles of MAb-001 were produced for the in vivo study and this was done using the Cell-PharmTM mini bioreactor system (Unisyn Technologies, Milford, MA 01757, USA). The harvested MAb-001 in D-MEM culture medium containing 10% fetal bovine serum was adjusted with CBVR to optical density value 0.49 using ELISA and about 0.2 m1 of this antibody was intraperitoneally (i.p.) injected into each fish.
Convalescent plasma preparation. Convalescent plasma was also used in the present study as a positive control. Fish that had recovered from a Cryptobia salmositica infection were challenged with 100 000 C . salrnositica. Two weeks after challenge, the fish were bled for convalescent plasma. The titre of the complement antibody in antisera was determined using the in vitro lysis test and was 1:64.
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) of MAb-001. Monoclonal antibody (hybridoma supernatant, approximately 5 pg protein per sample well) was mixed with an equal volume of Laemmli buffer without mercaptoethanol (Laemmli 1970) and was electrophoresed at 20°C into 10% running gel at 100 V for 1.5 h. Gels were stained with Coomassie brilliant blue or used for immunoblotting.
Western immunoblotting. After SDS-PAGE, the monoclonal antibody was transferred to nitrocellulose membrane (Towbin et al. 1979) . Electrophoretic transfer was for 2 h at 100 V. The membrane was blocked with a 5 % solution of skim milk in Tris buffered saline (TBS, pH ?S), washed in TBS, and incubated in 1:20 dilution of trout plasma (fish injected with either MAb-001 or CBVR) overnight at room temperature. A positive control of rabbit anti-mouse IgG [Sigma, diluted 1:3000 in 3 % skim milk/TBS with Tween 20 (TTBS)] was included. A nitrocellulose membrane incubated in naive fish plasma was used as a negative control. Membranes were washed in TTBS followed by TBS (2 washes each, 5 min per wash), and then incubated for 1 h in either goat antirabbit IgG or goat anti-trout imrnunoglobulin conjugated to alkaline phosphatase (Bio-Rad) diluted 1:3000 in 3 % skim milk/TTBS. After incubation the nitrocellulose was washed and incubated in the enzyme substrate, 5-bronio-4-chloro-3-indoly phosphate/Nitroblue tetrazolium (Bio-Rad) for 20 min.
Experimental design. Therapeutic action o f MAb-001 in fish with acute infections: Eighty rainbow trout were randomly divided into 4 groups (1, 2, 3 & 4, n = 20) and each group was further divided into 2 subgroups (a and b). Fish in l a , 2a, 3a and 4a were i.p. infected with 2000 (low dose) virulent Cryptobia salmositica, and fish in l b , 2b, 3b and 4b were infected with 20 000 (high dose) virulent C . salrnosjtica (from an infected fish). Blood (0.1 ml) was withdrawn weekly from the caudal vein of each fish using a needle and heparinlzed syringe and the parasitaemia was determined. Three weeks after infection, parasitaemias were high (about 1 to 5 X 106 ml-' blood) in all groups, and fish were ready for antibody treatment. Fish were bled to determine parasitaemias prior to i.p. antibody injection. Fish in group 1 were injected with MAb-001 (4% body weight in m1 per fish) and fish in group 2 were injected with convalescent plasma; fish in group 3 were injected with CBVR, and fish in group 4 were injected twice with MAb-001, the 2 injections being 3 d apart. Fish in groups 1, 2 and 3 were bled at 48 h after injection and parasitaemias were determined. Groups 1 , 2, 3 and 4 were bled at 1 wk after injection further to determine their parasitaemias.
Prophylactic effects o f MAb-001: An additional 80 rainbow trout were randomly divided into 4 groups (I, 11, 111 & IV, n = 20). In the first week, fish in group I were inlected with MAb-001 (the protein concentration was brought to 1 mg ml-' in CBVR; 4 % fish body weight in m1 per fish) every day and fish in group I1 were injected with MAb-001 every other day. Fish in group 111 were injected with convalescent plasma every day. Fish in group IV were injected with CBVR every day. One day after the first injection, each group was sub-divided into 2 sub-groups (a and b, n = 10). Fish in Ia, IIa, IIIa and IVa were i.p. infected with 2000 (low dose) virulent Cryptobia salrnositica (from an infected fish), and fish in sub-groups Ib, IIb, IIIb and IVb were infected with 20000 (high dose) virulent C. salrnositica.
Blood (0.1 ml) was withdrawn weekly from the caudal vein of each fish using a needle and heparinized syringe and the parasitaemia was determined.
Effects o f MAb-001 on the production o f antibodies in fish: To determine the effects of heterogeneous monoclonal antibody on the endogenous protective immunity in fish, plasma from fish in group I (prophylactic, injected with monoclonal antibody on Day 0, 1, 2, 3, 4, 5, 6, ?), group 1 (therapeutic, 3 wk after MAb injection) and in group IV (fish injected with CBVR at same time as group I) were collected after infection and heated at 45°C for 30 min (Sakai 1984) to inactivate the endogenous complement. The plasma were then stored at -20°C until used to detect complementfixing antibody (CFAb) against Cryptobia salmositica.
Additionally, plasma from fish in group I (6 wk after MAb injection) and group 1 (3 wk after MAb injection) were used to determine their humoral response against MAb-001 using immunoblot. Plasma from group IV was used as a negative controls.
Statistics: All data were analyzed using l-way analysis of variance. Multiple comparisons among means were made using Duncan's Multiple-Range Test when the analysis of variance value was significant (p < 0.05) (Steel & Torn 1980) .
RESULTS
Therapeutic action of MAb-001 in fish with acute infections Forty-eight hours after injection of MAb-001, the parasitaemia in fish in group 1 (injected with MAb-001 at 3 wk after infection) was significantly lowered (p < 0.05). The same result was seen in group 2 (injected with convalescent plasma). However, there were no significant differences in parasitaemias in group 3 before and after injection of CBVR (Fig. 1) . The parasitaemia in sub-group l a (low-dose infection) was lower than that in sub-group l b (high-dose infection) before antibody injection. However, a higher percentage of parasites (60 to 75%) in sub-group l b was eliminated than in sub-group l a (53 to 68%) after injection of MAb-001. However, the parasitaemias in sub-groups 2b and 3b were not different from subgroups 2a and 3a.
One week after MAb-001 injection, the parasitaemias in group 1 and in group 2 were still significantly lower than that prior to MAb injection (p < 0.05).
Although there was a slight drop in parasitaemia in group 3, there was no statistical difference between the parasitaemias prior to and after CBVR injection (Fig. 2) .
After a double dose of MAb-001 injection, the parasitaemias in sub-groups 4a and 4b were significantly lower (80 to 90%) than that prior to MAb injection. They were also 10 to 20% lower than in sub-groups l a and I b (injected with a single dose of MAb-001) at 1 wk after MAb-001 injection. However, there was no statistical difference in parasitaemias between a single-and a double-dose injected fish at 1 wk after MAb injection (Fig. 3) .
Prophylactic effects of MAb-001
Using the haematocrit centrifuge technique, 5/10 fish in sub-group Ia, 6/10 fish in sub-group Ib, 1/10 fish in sub-group IIa and 2/10 fish in sub-group IIb had de- than that prior to MAb injection tectable parasites at 1 wk after infection. No parasites were detected in fish in sub-group IIIa, and 1/10 fish in sub-group IIIb had detectable parasites. However, 7/10 fish in sub-groups IVa and IVb had detectable parasites at 1 wk after infection. Also, at 1 wk after infection the numbers of parasites in all groups infected with 2000 parasites were significantly (p < 0.05) lower than those in fish infected with 20 000 parasites. However, the number of the parasites in fish in group I1 (which received a MAb-001 injection Days after treatment every other day in the first week) was lower, but not to the extent of being statistically significant, than that in fish in group IV (which received a CBVR injection every day in the first week), although the number of parasites in fish in group I (which received a MAb-001 injection every day in the first week) was not significantly different from that in fish in group IV ( Table 1) . Parasitaemias in all groups peaked at 3 wk after infection. Fish in sub-groups Ia and Ib (injected with MAb every day during the first week of infection) had significantly higher parasitaemias than those in sub- groups IIIa and IIIb (injected with convalescent fish plasma, positive control), and in sub-groups IVa and IVb (injected with CBVR, negative control) (Fig. 4) . However, parasitaemias in sub-groups IIa and IIb (injected with MAb every other day during the first week of infection) were lower than in fish in sub-groups IVa and IVb (injected with CBVR negative control) and were similar to those in fish in sub-groups IIIa and IIIb (injected with convalescent plasma) although there were no significant differences in parasitaemias between fish in groups 11, 111 and IV (Fig. 5) . can be attributed neither to nonspecific factors in the hybridoma culture medium, since the hybridoma culture medium had no effects on Cryptobia salmositica (Feng & Woo 1996) , nor to the recipient's immune system, because control fish (injected with saline) had high parasitaemias at 48 h after injection of saline. Even at 1 wk after treatment, the parasitaemias in all groups of antibody-injected fish were still low. Although there was no statistical difference in parasitaemia before and after CBVR injection in the CBVRinjected fish, the numbers of parasites in MAb-injected fish and convalescent plasma-injected fish were statistically lower than in CBVR-injected fish. 
Complement-Fixing Antibody (CFAb) against
Crypto bia salrnositica
Complement-fixing antibodies were detected in both experimental (injected with MAb-001, group I) and control fish (injected with CBVR, group IV) at 5 wk after infection. However, 10/10 CBVR-injected fish had detectable complement-fixing antibodies, while only 3/10 MAb-injected fish had detectable complement-fixing antibodies.
Antibodies against MAb-001
Antibodies against MAb-001 were detected in MAbinjected infected fish (group I) using both dot blot and Western immunoblotting. When MAb-001 was transferred from gel to nitrocellulose after SDS-PAGE, it was detected as an intensive band (molecular weight about 150 kDa) by fish antibodies (group I, prophylactic). The intensity of the band in the positive control was lighter than that of fish injected with MAb-001 every day, and a very weak reaction was detected in group 1 (therapeutic). However, no reactions were seen in fish injected with CBVR and the negative control (Fig. 6) . These indicates that the transferred antibodies eliminated parasites in MAb-injected and convalescent plasma-injected fish.
There was no significant difference in parasitaemias between fish injected with a single or a double dose of MAb-001 at 1 wk after injection. This might be because the parasitaemias were low (at 48 h after MAb injection, parasitaemias were 3 times lower than before injection). This low parasitaemia reduced the chance of MAb-001 coming into contact with parasites before the antibody was inactivated by the fish because MAb-001 was of mouse origin. The antibody eliminated a higher percentage of parasites in fish with higher parasitaemias since the chance of contact between parasites and MAb-001 was greater.
Antibodies of the IgG 1 subclass are generally not efficient in activating complement and this is the case Fig. 6 . Detection of antibodies against MAb-001 in plasma from MAb-injected fish with immunoblot. Lane a: antibodies against MAb-001 were detected as an intensive band at 150 kDa when MAb-001 on the nitrocellulose strip was incubated with plasma from MAb-injected fish (group I, prophylactic); lane b: MAb-001 on the nitrocellulose was directly incubated with goat anti-mouse immunoglobulin; lane c: antibodies against MAb-001 were detected as an faint band in MAb-injected fish (group 1, therapeutic); lane d, e: no reaction was shown on the nitrocellulose strand after being incubated with plasma from saline-injected fish and naive fish. Number on the left is the pre-stained protein standard (Bio-Rad) with MAb-001. In an earlier study (Feng & Woo 1996) , we showed that they do not activate complement to lyse the parasite and mediate parasite cytotoxity via another mechanism. Alves et al. (1983) also reported a monoclonal antibody with complement-independent cytotoxity that decreased the incorporation of radiolabelled uridine and thymidine, and caused immobility and death in Trypanosoma cruzi. We (Feng & Woo 1996) suggested that MAb-001 mediates Cryptobia salmositica cytotoxity by affecting its metabolic process because parasites exposed to the antibody under in vitro conditions did not multiply and were dead in 2 to 3 wk. Since MAb-001 recognizes a glycoprotein on the surface membrane of C. salmositica, we assume that it may act on the parasite as a toxic lectin. Lectins bind to carbohydrate receptors on the cell membrane and inhibit membrane transport of nutrients or they enter the cytoplasn~ and inactivate protein synthesis. Freeman et al. (1980) reported 2 murine monoclonal antibodies (against merozoites of Plasmodium yoelii] which prevented the development of infection or eliminated an established infection with continuous administration of antibody to mice. Butscher & Faubert (1988) showed that mice injected with a murine monoclonal antibody (every other day before and after infection) had nearly 3 times fewer trophozoites than did mice treated with negative ascites. Our monoclonal antibody did not prevent disease nor eliminated the parasite in our prophylactic study because w e infected our fish with a low number of parasites, our monoclonal antibody was of mouse origin, and we stopped injecting our fish with MAb-001 a week after infection, when parasitaemias were still low. As pointed out earlier (in our therapeutic study), the antibody is effective when the parasitaemia is high; the chance of the antibody coming into contact with parasites in fish with a low parasitaemia was reduced, and in our prophylactic study in which the number of parasites was high (e.g. 3 to 4 wk after infection), most if not all the murine antibody would be degraded by the fish immune system. We detected antibodies against MAb-001 in our antibody-injected fish (5 wk after injection). However, Freeman et al. (1980) and Butcher & Faubert (1988) injected murine monoclonal antibodies into mice and they were successful because the monoclonal antibodies functioned as mouse immunoglobulins. Also, in our prophylactic study, fish injected with MAb-001 had significantly higher parasitaemias than fish injected with saline or convalescent plasma. One of the obvious reasons for the higher parasitaemias in MAb-001-injected fish is antigenic competition between our murine monoclonal antibody and the parasite antigen-? of 10 MAb-001-injected fish had no detectable complement-fixing antibodies against Cryptobia salmositica while 10 of 10 fish (injected with saline) had antibodies which lysed parasites under in vitro conditions. Though murine monoclonal antibodies against Ichthyophthirius mulfifiliis provided complete protection against infection in channel catfish, the mechanism of protection is believed to be different; the antibody when attached to the parasites forces the parasite to leave the host (Clark et al. 1996 ).
Our conclusion is that MAb-001 is therapeutic and that it significantly lowered the parasitaemia when injected into infected fish during the acute phase; however, the protection was only partial. Similarly, plasma from recovered and challenged fish did not eliminate all of the parasite in infected fish either. This could be because there were insufficient antibodies (in both the MAb-inoculum and in the convalescent plasma) to lyse all parasites or because both humoral and cellmediated immunity are necessary for complete protection.
